文献速递细菌感染、耐药与抗菌药物医院感染防控

延长输注β-内酰胺类抗菌药物用于血液病患者发热性中性粒细胞减少症治疗的疗效(BEATLE):一项随机、多中心、开放标签、优效性临床试验

Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial.
PubMed 文献 · Clin Microbiol Infect · 2024-10-19

在四家西班牙大学医院开展随机开放标签优效性试验,150例发热性中性粒细胞减少患者按1:1接受β-内酰胺类延长输注(EI,n=77)或间歇输注(II,n=73)。第5天治疗成功率EI组39/77(50.6%)vs II组46/73(63.0%),风险差-12.4%(95%CI -29.4至4.7,p=0.17)。作者认为 findings 不支持常规经验性使用延长输注。

要点

  • 第5天治疗成功率EI组50.6% vs II组63.0%,无统计学显著差异。
  • 75%和100% ƒuT>MIC药效学靶值在EI组更常达到。
  • 不良事件与30天死亡率两组无统计学显著差异。

核心结论

  • 研究结果不支持在发热性中性粒细胞减少症中常规经验性使用β-内酰胺类延长输注。
  • 作者建议进一步研究应考虑发热性中性粒细胞减少症的临床异质性,并聚焦于脓毒症或脓毒性休克及有微生物学证据的感染患者,尤其是对β-内酰胺类敏感性较低的微生物所致感染。

研究设计与样本

  • 随机、多中心、开放标签、优效性临床试验,在四家西班牙大学医院开展。
  • 2019年11月19日至2022年6月22日筛查295例,随机分配150例接受抗假单胞菌β-内酰胺类延长输注(EI,n=77)或间歇输注(II,n=73)。
  • 纳入接受造血干细胞移植或急性白血病化疗、因发热性中性粒细胞减少需经验性抗菌治疗的患者,首剂推注后按1:1随机分组。
  • 抗假单胞菌β-内酰胺类的选择由主治医师决定。
  • 主要终点为第5天治疗成功,定义为退热且未更改抗菌治疗方案。

主要发现

  • 意向性分析中,第5天治疗成功率EI组39/77(50.6%)vs II组46/73(63.0%),风险差-12.4%(95%CI -29.4至4.7,p=0.17)。
  • 经验性治疗达到75%和100% ƒuT>MIC药代动力学/药效学靶值的比例EI组高于II组。
  • 不良事件与30天死亡率两组间无统计学显著差异。

临床怎么用

  • 作者认为 findings 不支持常规经验性使用β-内酰胺类延长输注治疗发热性中性粒细胞减少症。

局限性

  • 作者指出需进一步研究,应考虑发热性中性粒细胞减少症的临床异质性,并聚焦于脓毒症或脓毒性休克及有微生物学证据的感染患者,尤其是对β-内酰胺类敏感性较低的微生物所致感染。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The efficacy of extended infusions (EI) of β-lactam antibiotics for optimising outcomes in febrile neutropenia is unclear. We assessed whether the administration of β-lactams was more effective in EI than in intermittent infusion (II) for the treatment of febrile neutropenia. METHODS: We performed a randomized, open-label, superiority clinical trial of patients with febrile neutropenia at four Spanish university hospitals. Patients undergoing haematopoietic stem cell transplantation or with acute leukaemia receiving chemotherapy who required empirical antibiotic treatment for febrile neutropenia were randomly assigned (1:1) to receive EI of β-lactam or II after a first dose in bolus. The choice of antipseudomonal β-lactam was left to the discretion of the attending physician. The primary endpoint was treatment success at day 5, defined as defervescence without modifying the antibiotic treatment. Secondary endpoints included adverse events, attainment of the pharmacokinetic/pharmacodynamic target of 50%, 75%, and 100%ƒuT > MIC, and 30-day mortality. RESULTS: From November 19, 2019 to June 22, 2022, 295 patients were screened for eligibility, of whom 150 were randomly assigned to receive EI (n = 77) or II (n = 73) of the antipseudomonal β-lactam of choice. In the intention-to-treat analysis, treatment success at day 5 was achieved in 39/77 patients (50.6%) receiving EI versus 46/73 patients (63.0%) receiving II (risk difference, -12.4%; 95% CI, -29.4 to 4.7; p 0.17). The pharmacokinetic/pharmacodynamic targets of 75% and 100% ƒuT > MIC for empirical treatment were achieved more frequently in the EI group. No statistically significant differences were found between groups in terms of adverse events or 30-day mortality. DISCUSSION: Our findings do not support the routine use of empirical EI of β-lactams in febrile neutropenia. Further studies should consider the clinical heterogeneity of febrile neutropenia and focus on patients with sepsis or septic shock and microbiologically documented infections, particularly those with infections caused by microorganisms less susceptible to β-lactams.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Laporte-Amargos J, Carmona-Torre F, Huguet M, et al. Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients (BEATLE): a randomized, multicentre, open-label, superiority clinical trial. Clin Microbiol Infect. 2024. PMID: 39433124. doi:10.1016/j.cmi.2024.10.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。